Founded in 2023 by Dr. Blair Leonard, the Thrombosis Research Program operates out of the Niagara Health Thrombosis Service, a community-based clinic. The program participates in observational and clinical trials (industry and investigator-initiated) in the areas of venous thromboembolism, cancer-associated thrombosis, atrial fibrillation, and peripheral arterial disease.
Current Team Members
Dr. Blair Leonard
Physician Lead
Kelsey Charlebois
Clinical Research Coordinator
Ongoing Studies
ASTER
ASTER: A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE
Cancer associated thrombosis (CAT) is a severe medical condition which is characterized by high incidence of blood clot (venous thromboembolism) recurrence and high risk of bleeding. This study aims to compare the effects of monthly administration of abelacimab, a novel Factor XI inhibitor with twice-daily administration of apixaban.
ASPIRE-AF
This study investigates compares the use of oral anticoagulation vs. no anticoagulation for the prevention of stroke and other adverse cardiovascular events in patients with transient perioperative atrial fibrillation after noncardiac surgery and additional stroke risk factors.
CONQUER-DVT
CONQUER-DVT: Colchicine to Quench the Inflammatory Response After Deep Vein Thrombosis
The purpose of this pilot trial is to assess the feasibility of a full-scale, double-blind, placebo-controlled, randomized trial assessing whether low-dose colchicine (0.5 mg daily) reduces the risk of post-thrombotic syndrome (PTS) in patients with proximal lower extremity deep vein thrombosis (DVT).
DETECT POAF
DETECT POAF: DETECTion of PeriOperative Atrial Fibrillation After Noncardiac Surgery
Perioperative atrial fibrillation (POAF) commonly occurs after noncardiac surgery and is often missed during clinical practice. A potential method to enhance POAF is continuous ECG monitoring. Patients in this study will receive up to 14 days of continuous ECG monitoring by wearing a portal monitoring device, starting within 72 hours after noncardiac surgery.
LEADER-PAD
This study will evaluate if anti-inflammatory therapy with colchicine will reduce vascular events in patients with symptomatic peripheral artery disease.
LILAC-TIMI 76
A study to evaluate the effect of abelacimab relative to placebo on the rate of ischemic stroke or systemic embolism (SE) in patients with atrial fibrillation (AF) who have been deemed by their responsible physicians or by their own decision to be unsuitable for oral anticoagulation therapy.
RADIANT
The investigators are studying whether treatment with a proton pump inhibitor called omeprazole reduces gastrointestinal bleeding in older adults taking blood thinners for a blood clot (venous thromboembolism).
START
Patients with cancer are prone to have blood clots which are usually treated with blood thinners. The main complication of blood thinners is bleeding. This is especially a concern when the number of platelets in the blood is lower than 50,000 per microliter. The role of platelets is to stop bleeding, so when the number of platelets is low, patients are at a higher risk of bleeding. Cancer patients are prone to have lower platelet numbers due to cancer therapies and/or cancer itself. This pilot trial will assess the feasibility of a larger trial that will compare a full dose of blood thinners along with platelet transfusion or a reduce dose of blood thinners without platelet transfusion.
SAVER
SAVER: Statins for Venous Event Reduction in Patients With Venous Thromboembolism
This study aims to treat recurrent blood clots and post-thrombotic syndrome with the addition of a statin to regular anticoagulation therapy.
TRIM-Line
TRIM-Line: Primary Thromboprophylaxis in Patients With Malignancy and Central Venous Catheters
The purpose of the full trial is to determine the efficacy and safety of prophylactic dose rivaroxaban to prevent blood clots (venous thromboembolism) among cancer patients with central venous catheters.
Completed Studies
Extraordinary Caring. Every Person. Every Time.
